SEC Form 4 · accession 0001415889-17-000634
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John David Hansen
Officer — PRESIDENT AND CEO · Director
Period of report
Apr 7, 2017
Accepted (ET)
Apr 11, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 7, 2017 | S | 666 | $2.005 | D | 72,499 | D | |
| Common StockF1 | Apr 10, 2017 | S | 560 | $2.00 | D | 71,939 | D | |
| Common StockF1 | Apr 11, 2017 | S | 250 | $2.00 | D | 71,689 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a portion of the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II of the reporting person's Form 4, as filed with the Securities and Exchange Commission on April 4, 2017. This sale is mandated by the Issuer's election under the equity incentive plan to require satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2 to $2.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.